Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to $64.1 million.

  • Enanta Pharmaceuticals' Cash from Financing Activities rose 138632.17% to $64.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $42.5 million, marking a year-over-year increase of 26825.27%. This contributed to the annual value of -$26.6 million for FY2025, which is 364.87% up from last year.
  • According to the latest figures from Q4 2025, Enanta Pharmaceuticals' Cash from Financing Activities is $64.1 million, which was up 138632.17% from -$8.3 million recorded in Q3 2025.
  • In the past 5 years, Enanta Pharmaceuticals' Cash from Financing Activities ranged from a high of $199.9 million in Q2 2023 and a low of -$8.3 million during Q3 2025
  • Moreover, its 5-year median value for Cash from Financing Activities was $139000.0 (2022), whereas its average is $11.5 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first skyrocketed by 475133.5% in 2023, then plummeted by 3126956.52% in 2024.
  • Enanta Pharmaceuticals' Cash from Financing Activities (Quarter) stood at $9.6 million in 2021, then crashed by 96.88% to $301000.0 in 2022, then tumbled by 2541.86% to -$7.4 million in 2023, then surged by 32.16% to -$5.0 million in 2024, then surged by 1386.32% to $64.1 million in 2025.
  • Its last three reported values are $64.1 million in Q4 2025, -$8.3 million for Q3 2025, and -$6.4 million during Q2 2025.